Healthcare cannabis and interest of young adult oncology sufferers

[ad_1]

Abstract

In Minnesota, health-related cannabis was authorized for use in 2014. From July 2015 to February 2019, our center certified 103 pediatric and young adult sufferers for the use of health-related cannabis under the qualifying circumstances of cancer and remedy-associated symptoms. Right here, we present a overview of the literature on health-related cannabis use in pediatric and young adult cancer sufferers. We also present demographic information on our sufferers certified for health-related cannabis. The most typical diagnoses have been leukemia/lymphoma (36%), brain tumors (37%), and malignant strong tumors (26%). The most typical indications have been chemotherapy-associated nausea, discomfort, and cancer cachexia. The age variety at certification was 1.four-28.7 years (median 15.three years). The time from cancer diagnosis to certification ranged from .five-197 months (median eight.9 months). The majority (94%) have been certified throughout their initial line of remedy. In the 32 sufferers who died from recurrent or progressive cancer, the time from certification to death was 1.three-30.three months (median four.four years). In spite of requesting certification, a subset (24%) by no means had health-related cannabis dispensed. In our practical experience, pediatric and young adult oncology sufferers are interested in health-related cannabis to support handle remedy-associated symptoms. Ongoing evaluation of this information will recognize the therapeutic efficacy of health-related cannabis.

Copyright © 2018 Elsevier B.V. All rights reserved.

Supply:Pubmed

 

PMID: 31212902 PMCID: PMC6617193 DOI: 10.3390/youngsters6060079

 

 

Skrypek MM1, Bostrom BCtwo, Bendel AEthree.

[ad_2]

Latest posts